Restart Life Sciences Corp. (NMLSF)
- Previous Close
0.0350 - Open
0.0350 - Bid --
- Ask --
- Day's Range
0.0350 - 0.0350 - 52 Week Range
0.0202 - 0.1500 - Volume
3,024 - Avg. Volume
9,065 - Market Cap (intraday)
1.163M - Beta (5Y Monthly) --
- PE Ratio (TTM)
4.80 - EPS (TTM)
0.0100 - Earnings Date Aug 25, 2025 - Aug 29, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
www.restartlife.coRecent News: NMLSF
View MorePerformance Overview: NMLSF
Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NMLSF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NMLSF
View MoreValuation Measures
Market Cap
1.44M
Enterprise Value
1.37M
Trailing P/E
6.63
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--